Connect Biopharma Hldgs Analyst Ratings
Connect Biopharma Hldgs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/13/2023 | 559.8% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
| 02/08/2023 | 823.73% | SVB Leerink | $9 → $7 | Maintains | Outperform |
| 06/02/2022 | 559.8% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 05/05/2022 | 97.94% | Piper Sandler | $25 → $1.5 | Downgrades | Overweight → Neutral |
| 05/04/2022 | 1087.65% | SVB Leerink | $22 → $9 | Maintains | Outperform |
| 01/06/2022 | 2803.14% | SVB Leerink | $32 → $22 | Maintains | Outperform |
| 07/02/2021 | 3462.95% | CICC | → $27 | Initiates Coverage On | → Outperform |
| 04/13/2021 | 3462.95% | Jefferies | → $27 | Initiates Coverage On | → Buy |
| 04/13/2021 | 4122.75% | SVB Leerink | → $32 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/13/2023 | 559.8% | 坎託·菲茨傑拉德 | → 5 美元 | 重申 | 超重 → 超重 |
| 02/08/2023 | 823.73% | SVB Leerink | 9 美元 → 7 美元 | 維護 | 跑贏大盤 |
| 06/02/2022 | 559.8% | 坎託·菲茨傑拉德 | → 5 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 05/05/2022 | 97.94% | 派珀·桑德勒 | 25 美元 → 1.5 美元 | 降級 | 超重 → 中性 |
| 05/04/2022 | 1087.65% | SVB Leerink | 22 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 01/06/2022 | 2803.14% | SVB Leerink | 32 美元 → 22 美元 | 維護 | 跑贏大盤 |
| 07/02/2021 | 3462.95% | CICC | → 27 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2021 年 4 月 13 日 | 3462.95% | 傑富瑞集團 | → 27 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 4 月 13 日 | 4122.75% | SVB Leerink | → 32 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for Connect Biopharma Hldgs (CNTB)?
Connect Biopharma Hldgs（CNTB）的目標價格是多少？
The latest price target for Connect Biopharma Hldgs (NASDAQ: CNTB) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $5.00 expecting CNTB to rise to within 12 months (a possible 559.80% upside). 2 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年9月13日公佈了Connect Biopharma Hldgs（納斯達克股票代碼：CNTB）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計CNTB將在12個月內上漲至59.80％（可能上漲559.80％）。去年，有2家分析公司公佈了評級。
What is the most recent analyst rating for Connect Biopharma Hldgs (CNTB)?
Connect Biopharma Hldgs（CNTB）的最新分析師評級是多少？
The latest analyst rating for Connect Biopharma Hldgs (NASDAQ: CNTB) was provided by Cantor Fitzgerald, and Connect Biopharma Hldgs reiterated their overweight rating.
Connect Biopharma Hldgs（納斯達克股票代碼：CNTB）的最新分析師評級由坎託·菲茨傑拉德提供，Connect Biopharma Hldgs重申了其增持評級。
When is the next analyst rating going to be posted or updated for Connect Biopharma Hldgs (CNTB)?
Connect Biopharma Hldgs（CNTB）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Connect Biopharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Connect Biopharma Hldgs was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Connect Biopharma Hldgs的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Connect Biopharma Hldgs的最後一次評級是在2023年9月13日提交的，因此你應該預計下一個評級將在2024年9月13日左右公佈。
Is the Analyst Rating Connect Biopharma Hldgs (CNTB) correct?
分析師評級Connect Biopharma Hldgs（CNTB）是否正確？
While ratings are subjective and will change, the latest Connect Biopharma Hldgs (CNTB) rating was a reiterated with a price target of $0.00 to $5.00. The current price Connect Biopharma Hldgs (CNTB) is trading at is $0.76, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的Connect Biopharma Hldgs（CNTB）評級，目標股價爲0.00美元至5.00美元。Connect Biopharma Hldgs（CNTB）目前的交易價格爲0.76美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。